{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}],"title":"Nodal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Skeletal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Skin/Superficial"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}],"title":"Soft Tissue/Visceral"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"The preliminary targeting properties of \\[68Ga\\]-NeoBOMB1 were to be assessed by summarizing the location of lesions identified by PET overall and split by GRPR positive and negative patients, as well as by tumor type. The location of lesions identified by aforementioned PET imaging were to be compared with the location of lesions identified by the comparable conventional imaging. Only descriptive analysis performed.","groups":[{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG000","title":"Breast"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG001","title":"Prostate"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG002","title":"Colorectal"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG003","title":"Non-Small Cell Lung Cancer (NSCLC)"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG004","title":"Small-Cell Lung Cancer (SCLC)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS). The results of the biopsied samples for all patients were positive for GRPR and thus the presentation of results according to GRPR expression were no longer suitable.","reportingStatus":"POSTED","timeFrame":"Conventional imaging collected within 3 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1","title":"Number of Participants With Lesions Detected by Conventional Imaging Per Location","type":"SECONDARY","unitOfMeasure":"Participants"}